PATENT COOPERATION TREATY

PCT To: Perstorp Specialty Chemicals AB 284 80 Perstorp Sverige Date of mailing (Adaymonth/gear) Date of mailing (Ad	PATENT COOPERATION TREES				
Applicant's or agent's file reference	To: Perstorp Specialty Chemicals AB 284 80 Perstorp	WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)			
International application No. PCT/SE 2005 / 000089 27.01.2005 23.02.2004	U. Clareference	FOR FURTHER ACTION See paragraph 2 below			
International application No. PCT/SE 2005/00089 27.01.2005 23.02.2004 International Patent Classification (IPC) or both national classification and IPC C08K 3/10 Applicant Perstorp Compounds AB et al 1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain observations on the international application Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the If this opinion is, as provided above, considered to be a written opinion of the If this opinion is, as provided above, considered to be a written opinion of the If this opinion is, as provided above, considered to be a written opinion of the Orthops of the International Surceau under Rule 66.1bis(b) that Written opinions of this International Surceau inder Rule 66.1bis(b) that Orthops opinions is as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the If this opinion is, as provided above, considered to be a written opinion of the PEA, the applicant is invited to submit to the If this opinion is, as provided above, considered to be a written opinion of the PEA, the applicant is invited to submit to the IPEA as written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing IPEA a written reply together, where appropriate, with amendments, before the expiration of 5 months from the date of mailing IPEA a written reply together		(/ whhaar)			
International patent Classification (IPC) or both national classification and IPC		date (day/month/year) Priority date (day/month/year)			
International Patent Classification (IPC) or both national classification and IPC COBK 3/10 Applicant Perstorp Compounds AB et al 1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Box No. II Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis. 1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the If at the antison one to be IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1 bis(1) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing in IPEA as written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing in IPEA as written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing in IPEA as written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing in IPEA as written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing in IPEA as written reply together, where a	International application 100	23.02.200			
Applicant Perstorp Compounds AB et al 1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion	PCT/SE 2005/000005	sification and IPC			
Applicant Perstorp Compounds AB et al	International Patent Classification (II o) of the				
1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion					
1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion	Applicant Description Compounds AB et al				
Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an International Preliminary Examining Authority will not be so considered. written opinions of this International Searching Authority will not be so considered. written opinion of the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing IPEA a written reply together, where appropriate, with amendments, before the expiration of 2 months from the priority date, whichever expires later. For further opinions, see Form PCT/ISA/220. Name and mailing address of the ISA/SE Patent - och registreringsverket Box 5055 Barbro Nilsson/MP Telephone No. +46 8 782 25 00					
Name and mailing address of the ISA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Telephone No. +46 8 782 25 00	Box No. II Priority Box No. III Non-establishment of opinion with More and the statement under Rule 4 applicability; citations and explant Box No. VI Certain documents cited Box No. VII Certain defects in the internation Box No. VIII Certain observations on the international Preliminary Examining Authority ("IPE Authority other than this one to be IPEA and the chose written opinions of this International Searching Authority if this opinion is, as provided above, considered to be IPEA a written reply together, where appropriate, with of Form PCT/ISA/220 or before the expiration of 22 For further opinions, see Form PCT/ISA/220.	An regard to novelty, inventive step and industrial applicability (3bis.1(a)(i) with regard to novelty, inventive step or industrial nations supporting such statement (a) application (b) a supplication (c) a written opinion of the national applicant chooses an apply where the applicant chooses an apply will not be so considered. (c) a written opinion of the IPEA, the applicant is invited to submit to the at a written opinion of the IPEA, the applicant is invited to submit to the analysis of the priority date, whichever expires later.			
Name and mailing address of the ISA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Telephone No. +46 8 782 25 00		Aush orized officer			
Patent- och registreringsvers Box 5055 S-102 42 STOCKHOLM Telephone No. +46 8 782 25 00	Name and mailing address of the ISA/SE	and the control of th			
S-102 42 STOCKHOLM Telephone No. +46 8 782 25 00	Patent- och registiering	Barbro Nilsson/MP			
	S-102 42 STOCKHOLM	Telephone No. +46 8 782 25 00			

Form PCT/ISA/237 (cover sheet) (January 2004)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/SE 2005/000089

ox No. I	Basis of this opinion
which it w	d to the language, this opinion has been established on the basis of the international application in the language in as filed, unless otherwise indicated under this item. is opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 d 23.1(b)).
	rd to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the
 With regard in the claimed in the clai	rd to any nucleotide and/or amino actu sequence discourse the properties of the basis of:
	f material
	a sequence listing
	table(s) related to the sequence listing
b. forma	of material
	in written format
	in computer readable form
c. time	of filing/furnishing contained in the international application as filed.
<u> </u>	filed together with the international application in computer readable form.
1	filed together with the international application in company
	furnished subsequently to this Authority for the purposes of search.
3.	furnished subsequently to this Authority for the purposes of search. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	furnished subsequently to this Authority for the purposes of search. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been additional copies is identical to
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
	furnished subsequently to this Authority for the purposes of search. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or does not go beyond the subsequent or additional copies is identical to filed or does not go beyond the application as filed, as appropriate, were furnished.
	furnished subsequently to this Authority for the purposes of search. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or does not go beyond the subsequent or additional copies is identical to filed or does not go beyond the application as filed, as appropriate, were furnished.
	furnished subsequently to this Authority for the purposes of search. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or does not go beyond the subsequent or additional copies is identical to filed or does not go beyond the application as filed, as appropriate, were furnished.

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/SE 2005/000089

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
-----------	--

1. Statement			
Novelty (N)	Claims	1-16	YES
Novelty (IV)	Claims	17	NO
Inventive step (IS)	Claims Claims	1-16	_ YES
		17	_ NO
Industrial applicability (IA)	Claims	1-17	YES
	Claims		_ NO
	•		

2. Citations and explanations:

The claimed invention relates to use of a plastic composition for preparation of moulded products respectively lacquered or painted products. The aim of the invention is to provide the products with a surface having antivirus activity even against SARS coronavirus.

Reference is made to the following document/documents:

D1:WO 0179349 A1

D2:US 5393809 A

D3:DE 10138568 A1

D4:EP 0606762 A2

Documents D1 to D4 disclose moulded products made of a plastic composition containing a silver salt e.g. a silver nitrate, silver sulphate (see D2, claims 1, 4 and column 1, lines 7-15) or silver chloride (refer to D4, abstract, claims 1 and 9-12).

None of the cited documents discloses the use of a plastic composition for preparation of moulded products or lacquered or painted products provided with a surface having antivirus activity even against SARS coronavirus.

However, the moulded product defined in claim 17 is disclosed in the cited documents. Consequently, the subject matter in claim 17 lacks novelty and inventive step.